NCT02417337

Brief Summary

Root canal therapy will ideally eliminate post-endodontic pain but occasionally analgesics are needed to diminish the pain \[Owatz et al 2007\]. Development of pain after completion of root canal treatment may undermine patients' confidence in the procedure and the clinician \[Albashaireh and Alnegrish 1998\]. Non-steroidal anti-inflammatory drugs are one of the most frequently taken analgesic medications for dental pain. Their popularity attributed to their efficacy in relieving pain and fever and low side effect profile at therapeutic doses \[Attar et al 2008\]. Mono-therapy analgesic has a low effect on dental pain. Improvement was performance by combining analgesics with different mechanisms of action without raising any adverse effects \[Mehlisch 2002\], was effective in controlling moderate to severe pain. The combination of a non-steroidal anti-inflammatory drug (NSAID) and paracetamol has shown additive analgesia for treating dental pain in several studies \[Breivik et al1999, Keiser and Hargreaves 2002\]. Endodontic treatment with a lower prevalence of postoperative pain is usually the treatment of choice.There have been no controlled dental studies evaluating the additive effects of combining a non-steroidal anti-inflammatory drug with paracetamol. Breivik et al1999 \& Menhinick et al 2004 found that a combination of acetaminophen and ibuprofen was more effective than ibuprofen alone in managing postoperative pain \[Breivik et al1999 \& Menhinick et al 2004\]. Aim of the present study, to evaluate the efficacy of the paracetamol when used alone and in combinations with three groups of drugs to control postoperative endodontic pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
185

participants targeted

Target at P75+ for phase_2 pain

Timeline
Completed

Started Aug 2012

Typical duration for phase_2 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2012

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 30, 2015

Completed
16 days until next milestone

First Posted

Study publicly available on registry

April 15, 2015

Completed
11.2 years until next milestone

Results Posted

Study results publicly available

June 25, 2026

Completed
Last Updated

June 25, 2026

Status Verified

June 1, 2026

Enrollment Period

2 years

First QC Date

March 30, 2015

Results QC Date

October 29, 2016

Last Update Submit

June 1, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain Score on Numerical Rating Scale of Pain (NRS-11)

    (NRS-11) numerical rating scale of pain between 0 (better) and 10 (worse) before and after treatment

    8 hours

Secondary Outcomes (1)

  • Mean of Pain Reduction Stratified by Sex and Jaw Type on Numerical Rating Scale (NRS-11)

    8 hours

Study Arms (5)

Group I

ACTIVE COMPARATOR

paracetamol 1000mg

Drug: Paracetamol

Group II

EXPERIMENTAL

ibuprofen 600mg + paracetamol 1000mg,

Drug: ParacetamolDrug: Ibuprofen

Group III

EXPERIMENTAL

Mefenamic acid 500mg + Paracetamol 1000mg

Drug: ParacetamolDrug: Mefenamic Acid

Group IV

EXPERIMENTAL

Diclofenac K 50mg + paracetamol 1000 mg

Drug: ParacetamolDrug: Diclofenac

Group V

OTHER

Placebo, no medication

Other: Placebo

Interventions

NSAID

Also known as: Acetaminophen
Group IGroup IIGroup IIIGroup IV

NSAID

Also known as: isobutylphenyl propanoic acid
Group II

NSAID

Also known as: Fenamate
Group III

NSAID

Also known as: Voltaren
Group IV
PlaceboOTHER

empty double gelatinous capsules, having similar weight and appearance of the medications

Also known as: no medication
Group V

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Spontaneous pain moderate to severe on the verbal rating scale (VRS-4), ranging from 4-10 score based on the numerical rating scale (NRS-11).
  • Adult patients presented for emergency endodontic treatment with a symptomatic maxillary or mandibular tooth (anterior and premolar) with a pulpal diagnosis of Irreversible pulpitis and normal periapex.
  • Patient choose to have root canal treatment for pain of endodontic origin.
  • The patient presented with American Society of Anesthesiologists (ASA) I or II medical history (ASA 1963).
  • The patient had read and thoroughly understood the pain score level sheet

You may not qualify if:

  • Patients below 18 years of age;
  • Analgesic taken within the last 4 hours;
  • History of allergy to NSAIDs, paracetamol or local anaesthetics;
  • History of uncontrolled systemic disease \[gastrointestinal (GI) disorders, oesophageal reflux, active asthma, decreased hepatic function, haemorrhagic disorders, or poorly controlled diabetes mellitus\].
  • Patients currently taking opioids, monoamine oxidase inhibitors, tricyclic antidepressants, carbamazepine, diuretics, or anticoagulants;
  • There was history of opioid addiction or abuse; and
  • Pregnant or nursing female patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Khartoum, Faculty of Dentistry,

Khartoum, 111-11, Sudan

Location

Related Publications (8)

  • Owatz CB, Khan AA, Schindler WG, Schwartz SA, Keiser K, Hargreaves KM. The incidence of mechanical allodynia in patients with irreversible pulpitis. J Endod. 2007 May;33(5):552-6. doi: 10.1016/j.joen.2007.01.023. Epub 2007 Mar 6.

  • Albashaireh ZS, Alnegrish AS. Postobturation pain after single- and multiple-visit endodontic therapy. A prospective study. J Dent. 1998 Mar;26(3):227-32. doi: 10.1016/s0300-5712(97)00006-7.

  • Attar S, Bowles WR, Baisden MK, Hodges JS, McClanahan SB. Evaluation of pretreatment analgesia and endodontic treatment for postoperative endodontic pain. J Endod. 2008 Jun;34(6):652-5. doi: 10.1016/j.joen.2008.02.017. Epub 2008 Apr 2.

  • Mehlisch DR. The efficacy of combination analgesic therapy in relieving dental pain. J Am Dent Assoc. 2002 Jul;133(7):861-71. doi: 10.14219/jada.archive.2002.0300.

  • Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study. Clin Pharmacol Ther. 1999 Dec;66(6):625-35. doi: 10.1053/cp.1999.v66.103629001.

  • Keiser K, Hargreaves K.Building effective strategies for the management of endodontic pain. Endodontic Topics, Volume 3, Issue 1, pages 93-105, November 2002

    RESULT
  • Menhinick KA, Gutmann JL, Regan JD, Taylor SE, Buschang PH. The efficacy of pain control following nonsurgical root canal treatment using ibuprofen or a combination of ibuprofen and acetaminophen in a randomized, double-blind, placebo-controlled study. Int Endod J. 2004 Aug;37(8):531-41. doi: 10.1111/j.1365-2591.2004.00836.x.

  • Elzaki WM, Abubakr NH, Ziada HM, Ibrahim YE. Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain. J Endod. 2016 Jun;42(6):835-42. doi: 10.1016/j.joen.2016.02.014. Epub 2016 Apr 12.

MeSH Terms

Conditions

PainPain, Postoperative

Interventions

AcetaminophenIbuprofenMefenamic AcidDiclofenac

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic Processes

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPhenylpropionatesAcids, CarbocyclicCarboxylic AcidsFenamatesortho-AminobenzoatesAminobenzoatesBenzoatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenylacetates

Limitations and Caveats

One limitation was the time frame for the analysis of pain; more information would have been available if there were a 24-hour outcome line

Results Point of Contact

Title
Neamat Abubakr
Organization
University of Khartoum

Study Officials

  • Neamat Abubakr, BDS,MDSc,PhD

    Faculty of Dentistry, University of Khartoum

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer at Faculty of Dentistry

Study Record Dates

First Submitted

March 30, 2015

First Posted

April 15, 2015

Study Start

August 1, 2012

Primary Completion

August 1, 2014

Study Completion

January 1, 2015

Last Updated

June 25, 2026

Results First Posted

June 25, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Not shared

Locations